US
US Plasma-Derived Therapies Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $14.53 Bn.
Canada at 7.3% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$8.21 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $13.83 Bn | — | — |
| 2025 (base) | $14.53 Bn | +$705.3 Mn | — |
| 2026 (forecast) | $15.28 Bn | +$741.2 Mn | +5.1% |
| 2027 (forecast) | $16.05 Bn | +$779.0 Mn | +10.5% |
| 2028 (forecast) | $16.87 Bn | +$818.8 Mn | +16.1% |
| 2029 (forecast) | $17.73 Bn | +$860.5 Mn | +22% |
| 2030 (forecast) | $18.64 Bn | +$904.4 Mn | +28.2% |
| 2031 (forecast) | $19.59 Bn | +$950.5 Mn | +34.8% |
| 2032 (forecast) | $20.59 Bn | +$999.0 Mn | +41.7% |
| 2033 (forecast) | $21.64 Bn | +$1.05 Bn | +48.9% |
| 2034 (forecast) | $22.74 Bn | +$1.10 Bn | +56.5% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$14.53 Bn
Canada
$3.12 Bn
China
$2.87 Bn
Japan
$2.50 Bn
Germany
$1.49 Bn
France
$1.07 Bn
UK
$1.01 Bn
Brazil
$946.0 Mn
Italy
$875.8 Mn
Ecuador
$761.7 Mn
Spain
$723.5 Mn
India
$715.7 Mn
Saudi Arabia
$632.0 Mn
Mexico
$592.4 Mn
Australia
$415.7 Mn
Russia
$383.0 Mn
New Zealand
$363.3 Mn
South Africa
$220.7 Mn
UAE
$206.2 Mn
Egypt
$92.1 Mn
Philippines
$89.0 Mn
Malaysia
$65.4 Mn
Hong Kong
$54.1 Mn
Singapore
$42.8 Mn
Thailand
$39.9 Mn
Kenya
$23.7 Mn
Plasma-derived therapies are medicines made from donated blood plasma, such as immunoglobulins, albumin and clotting factors.
Key segments of the plasma-Derived Therapies market include product (Immunoglobulins, Albumin and Coagulation Factors) and application (Immunology, Hematology and Critical Care).
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.
Ready-to-use formulations, biosimilars and supply security programmes give the plasma-Derived Therapies market room to grow.
Drug shortages, price controls, generic competition and strict hospital budgets hold back the plasma-Derived Therapies market.
The plasma-Derived Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for plasma-Derived Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Plasma-Derived Therapies right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 3 shared keywords
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
Medical Devices · US
Healthcare Services · US
Healthcare Services · US
Healthcare Services · US
Healthcare Services · US
Healthcare Services · US